Downregulation of miR-145 expression in oral squamous cell carcinomas and its clinical significance

Onkologie

Volumn 36, Issue 4, 2013, Pages 194-199

  Gao, Ling ^a,b   Ren, Wenhao ^a   Chang, Su'e ^b   Guo, Bo ^b   Huang, Shuo ^a   Li, Menghe ^b   Guo, Youmin ^c   Li, Zongfang ^d   Song, Tusheng ^b   Zhi, Keqian ^a,d   Huang, Chen ^b,d  

^a Stomatological Hospital   (China)

^b University College of Medicine   (China)

^c THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^d XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Clinicopathologic factors; Mir 145; Oral squamous cell carcinoma

Indexed keywords

MICRORNA 145;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MOUTH NEOPLASMS;

EID: 84876193729     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000349956     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.
2. Forastiere A, Koch W, Trotti A, Sidransky D: Head and neck cancer. N Engl J Med 2001;345: 1890-1900.
3. Bell RB, Kademani D, Homer L, Dierks EJ, Potter BE: Tongue cancer: Is there a difference in survival compared with other subsites in the oral cavity? J Oral Maxillofac Surg 2007;65:229-236.
4. Bagan J, Sarrion G, Jimenez Y: Oral cancer: clinical features. Oral Oncol 2010;46:414-417.
5. Esquela-Kerscher A, Slack FJ: OncoMIRs-microRNAs with a role in cancer. Nature Reviews Cancer 2006;6:259-269.
6. Massano J, Regateiro FS, Januario G, Ferreira A: Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endod 2006;102:67-76.
7. Yang CJ, Shen WG, Liu CJ, Chen YW, Lu HH, Tsai MM, Lin SC: Mir-221 and mir-222 expression increased the growth and tumorigenesis of oral carcinoma cells. J Oral Pathol Med 2011;40:560-566.
8. Lin SC, Liu CJ, Lin JA, Chiang WF, Hung PS, Chang KW: Mir-24 up-regulation in oral carcinoma: positive association from clinical and in vitro analysis. Oral Oncol 2010;46:204-208.
9. Liu CJ, Kao SY, Tu HF, Tsai MM, Chang KW, Lin SC: Increase of microRNA mir-31 level in plasma could be a potential marker of oral cancer. Oral Dis 2010;16:360-364.
10. Henson BJ, Bhattacharjee S, O'Dee DM, Feingold E, Gollin SM: Decreased expression of mir-125b and mir-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer 2009;48: 569-582.
11. Shin KH, Bae SD, Hong HS, Kim RH, Kang MK, Park NH: Mir-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating k-ras. Biochem Biophys Res Commun 2010;404:896-902.
12. Kim SJ, Oh JS, Shin JY, Lee KD, Sung KW, Nam SJ, Chun KH: Development of microRNA-145 for therapeutic application in breast cancer. J Controlled Release 2011;155:427-434.
13. Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK, Aigner A: MicroRNA replacement therapy for mir-145 and mir-33a is efficacious in a model of colon carcinoma. Cancer Res 2011;71: 5214.
14. Cho WCS, Chow ASC, Au JSK: Mir-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biology 2011;8:125-131.
15. Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008;3:1101-1108.
16. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10: 704-714.
17. Jin W, Grant J, Stothard P, Moore S, Guan L: Characterization of bovine miRNAs by sequencing and bioinformatics analysis. BMC Mol Biol 2009; 10:90.
18. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-773.
19. Pena JT, Sohn-Lee C, Rouhanifard SH, Ludwig J, Hafner M, Mihailovic A, Lim C, Holoch D, Berninger P, Zavolan M, Tuschl T: miRNA in situ hybridization in formaldehyde and EDC-fixed tissues. Nat Methods 2009;6:139-141.
20. Aravin A, Tuschl T: Identification and characterization of small RNAs involved in RNA silencing. FEBS Lett 2005;579:5830-5840.
21. Griffiths-Jones S, Saini HK, Van Dongen S, Enright AJ: Mirbase: tools for microRNA genomics. Nucleic Acids Res 2008;36:D154-D158.
22. Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, Lai L, Jiang BH: Mir-145 directly targets p70s6k1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 2011;40:761-774.
23. Zaman M, Chen Y, Deng G, Shahryari V, Suh S, Saini S, Majid S, Liu J, Khatri G, Tanaka Y: The functional significance of microRNA-145 in prostate cancer. Br J Cancer 2010;103:256-264.
24. Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N, Akao Y: Decreased expression of microRNA-143 and-145 in human gastric cancers. Oncology 2009; 77:12-21.
25. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065.
26. Van Kouwenhove M, Kedde M, Agami R: MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nature Reviews Cancer 2011;11:644-656.
27. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R: Altered expression of mir-21, mir-31, mir-143 and mir-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007;72: 397-402.
28. Wu BL, Xu LY, Du ZP, Liao LD, Zhang HF, Huang Q, Fang GQ, Li EM: miRNA profile in esophageal squamous cell carcinoma: downregulation of mir-143 and mir-145. World J Gastroenterol 2011;17:79-88.
29. Lee SJ, Kim SJ, Seo HH, Shin SP, Kim DH, Park CS, Kim KT, Kim YH, Jung JS, Kim IH: Over-expression of mir-145 enhances the effectiveness of HSVTK gene therapy for malignant glioma. Cancer Lett 2012;Epub ahead of print.
30. Ibrahim AF, Weirauch U, Thomas M, Grunweller A, Hartmann RK, Aigner A: MicroRNA replacement therapy for mir-145 and mir-33a is efficacious in a model of colon carcinoma. Cancer Res 2011;71: 5214-5224.
31. Kim SJ, Oh JS, Shin JY, Lee KD, Sung KW, Nam SJ, Chun KH: Development of microRNA-145 for therapeutic application in breast cancer. J Control Release 2011;155:427-434.
32. Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, Lai L, Jiang BH: Mir-145 directly targets p70s6k1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 2012;40:761-774.